 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Leukemia
| Abraxane |
| Nanoparticle formulation of taxane |
American Pharmaceuticals |
II |
|
| AG-858 |
Vaccine |
Antigenics |
II (CML) |
| AMN107 |
Bcr-Abl, Kit, PDGFR inhibitor |
Novartis |
II |
| AP1903 |
Gene therapy |
Ariad Pharmaceuticals |
II |
| Arranon (nelarabine) |
Nucleoside analog |
GlaxoSmithKline |
Approved 10-28-05 T-ALL, T-LBL |
| BCX-1777 |
ONO inhibitor |
Biocryst |
I ALL |
| BL22 immunotoxin |
immunotoxin |
NCI |
II(Cladaribine resistant HCL |
| Campath (alemtuzumab) |
Monoclonal antibody |
Ilex Berlex |
III |
| Ceflatonin (homoharringtonine or HHT) |
Plant ankaloid |
Chem Genex |
I CML, APL |
| CEP-701 |
FLT3 inhibitor |
Cephalon |
II |
| Ceplene (histamine dihydrochloride) |
Synthetic nucleoside analog |
Maxim Pharmaceuticals |
III (AML) |
| Cloretazine (VNP4010M) |
Alkylating agent |
Vion |
II AML |
| Clofarex (clofarabine) |
Purine nucleoside |
Bioenvision |
II |
| Cloretazine (VNP4010M) |
DNA damaging alkylating agent |
VION |
I |
| CP461 |
Apoptotic antineoplastic |
Cell Pathways |
II |
| Dacogen (decitabine) |
DNA methyltransferase inhibitor |
MGI |
FDA submission(MDS)pending approval II AML, CML |
| Genasense (oblimersen) |
Antisense |
Genta and Aventis |
II (CML) |
| GTI-2040 |
Antisense |
Lorus Therapeutics |
II AML |
| GVAX |
Vaccine |
Cell Genesys |
II |
| GVH313 |
MoAb |
Gentic Therapy |
I CML |
| IDM-4 |
MoAb |
IDM Biotech |
I/II |
| Interleukin-2 |
Cytokine |
Valentis |
III (AML) |
| ISF154 |
Vaccine |
Tragen Pharmaceuticals |
II (CLL) |
| MG98 |
2nd generation antisense |
Methyl Gene |
I AML |
| MLN 518 |
Tyrosine kinase inhibitor (FLT3, PDGFR, c-KIT) |
Millennium |
II |
| Mylotarg (gemtuzumab) |
Monoclonal antibody |
Wyeth |
Approved and phase II (AML) |
| Onco TCS |
Liposomal vinca alkaloid |
Inex Enzon |
I ALL |
| Ontak (denileukin) |
Fusion protein |
Ligand Pharmaceuticals |
II |
| Peg-intron (peginterferon alfa-2b) |
Pegylated interferon alfa-2b |
Schering-Plough |
III |
| PKC412 (midostaurin) |
Tyrosine kinase inhibitor |
Novartis |
II |
| Remitogen (alpolizumab) |
MoAb |
Protein Desing Lab |
I/II ALL, CLL |
| Rituxan (rituximab) |
CD 20 monoclonal antibody |
Idec Pharmaceuticals and Genentech |
I,II |
| SAHA (superoylanilide hydroxamic acid |
HDAC inhibitor |
Aton |
I |
| Sarasar (lonafarnib) |
Oral Farnesyl Protein Transferase Inhibitor |
Schering-Plough |
II |
| SDX-101 (R-etodolac) |
Apoptotic |
Salmedix |
II |
| Siosix |
Recombinant human IL-6 |
Serono |
I AML |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
II (ALL, AML) |
| Trisenox (arsenic trioxide) |
Arsenic |
Cell Therapeutics |
II (APL) |
| Troxatyl Troxacitibine |
deoxycytidine analogue |
Shire BioChem |
II |
| Zarnestra (tipifarnib) |
Farensyl transferase inhibitor |
Johnson & Johnson |
II |
| Zosuquidar trihydrochloride (LY335979) |
P-glycoprotein inhibitor |
Eli Lilly |
III (AML) |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
